Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.87B 4.2B 3.94B 3.59B 6.75B 465B 6.84B 46.2B 18.1B 233B 18.27B 17.87B 775B P/E 2026 *
46.8x
P/E 2027 * 33x
Enterprise Value 3.8B 3.28B 3.08B 2.8B 5.27B 363B 5.34B 36.08B 14.14B 182B 14.27B 13.96B 605B EV / Sales 2026 *
2.99x
EV / Sales 2027 * 2.54x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+1.52%
1 week-2.53%
Current month+10.73%
1 month+11.89%
3 months+38.45%
6 months+24.81%
Current year+7.24%
1 week 27.9
Extreme 27.9
29.85
1 month 24.23
Extreme 24.232
29.85
Current year 19.89
Extreme 19.89
29.85
1 year 19.69
Extreme 19.69
29.85
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 20/09/2024
Director of Finance/CFO 52 10/09/2021
Chief Tech/Sci/R&D Officer - 04/08/2025
Director TitleAgeSince
Director/Board Member 68 01/05/2008
Chairman 55 10/06/2016
Director/Board Member 73 25/11/2015
Date Insider Type Main position Quantity % Market Cap.
6/8/26 Fiscal year

Chief Financial Officer

42,876 0.0250%
30/7/26 Sell

Chief Technology Officer

-16,558 0.0097%
6/2/26 Fiscal year

General Counsel

32,838 0.0194%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-2.53%+14.31%-0.88% 4.87B
+0.68%-2.28%+1.91%+19.70% 48.42B
+3.79%+2.10%+479.73%+621.44% 43.66B
+3.59%+0.20%+12.66%+87.09% 39.51B
+0.61%-1.77%+23.46%+10.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.59%-2.36% - - 16.32B
+1.52%-2.98%+26.26%+130.49% 16.15B
-0.62%-0.06%+3.95%+27.74% 14.16B
+2.60%+3.50%+82.63%+43.44% 13.37B
Average +1.36%-0.64%+73.95%+110.91% 26.8B
Weighted average by Cap. +1.56%-0.67%+98.45%+146.72%

Financials

2026 *2027 *
Net sales 1.27B 1.1B 1.03B 938M 1.76B 122B 1.79B 12.07B 4.73B 60.89B 4.77B 4.67B 203B 1.43B 1.23B 1.16B 1.05B 1.98B 137B 2.01B 13.58B 5.32B 68.5B 5.37B 5.25B 228B
Net income 105M 90.8M 85.18M 77.59M 146M 10.06B 148M 999M 391M 5.04B 395M 386M 16.76B 158M 136M 128M 117M 219M 15.11B 222M 1.5B 588M 7.57B 593M 581M 25.19B
Net Debt -1.07B -920M -863M -786M -1.48B -102B -1.5B -10.12B -3.97B -51.06B -4B -3.92B -170B -1.23B -1.07B -999M -910M -1.71B -118B -1.74B -11.71B -4.59B -59.1B -4.63B -4.53B -197B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
18/08/26 USD 28.64 +1.42% 307,497
14/08/26 USD 28.24 -0.49% 1,062,578
13/08/26 USD 28.38 -3.63% 1,507,221
12/08/26 USD 29.45 +0.14% 1,409,739
11/08/26 USD 29.41 +0.07% 1,346,523
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
28.24USD
Average target price
33.65USD
Spread / Average Target
+19.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock